Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Feb 16, 2022; 10(5): 1498-1507
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1498
Table 1 Clinical characteristics of patients with gastric cancer
Clinical parameters
Group L
Group M
P value
Gender0.531
Male149
Female88
Age group (yr)0.748
65-691110
70-75117
ECOG score0.561
0148
155
234
Tumor location0.667
Proximal23
Middle42
Distal1612
Tumor stage0.192
cT3125
cT4a99
cT4b13
PCI scores0.508
< 20159
≥ 2078
Abdominal infection (cases)200.495
pulmonary infection (cases)111.000
Urinary tract infection (cases)010.436
Myelosuppression system (grade 3/4, cases)600.027
Blood transfusion therapy (cases)400.118
Average length of stay (d)18.716.10.045
Table 2 Univariate and multivariate analysis of prognostic factors of gastric cancer patients
Clinical parametersUnivariate analysis
Multivariate analysis
HR (95%CI)
P value
HR (95%CI)
P value
Gender (male vs female)0.858 (0.424-1.734)0.670
Age (< 70 vs ≥ 70)1.139 (0.564-2.301)0.717
Group (L vs M)1.467 (0.714-3.016)0.297
T stage (T3 vsT4 or above)2.403 (1.118-5.163)0.0251.457 (0.554-3.832)0.445
Tumor marker (normal vs high)1.009 (0.473-2.153)0.981
CD4/CD8 (< 1 vs ≥ 1)2.505 (1.147-5.467)0.0212.051 (0.8534.933)0.109
Myelosuppression (1/2 vs 3/4)3.570 (1.291-9.874)0.0143.220 (0.985-10.530)0.053
Times of chemotherapy after HIPEC (< 6 vs ≥ 6)0.143 (0.060-0.343)0.0000.210 (0.070-0.634)0.006
PCI (< 20 vs ≥ 20)2.444 (1.105-5.404)0.0271.247 (0.417-3.725)0.693
Ascites (exist1 vs none)4.106 (1.746-9.658)0.0013.084 (0.948-10.027)0.061